1. Home
  2. UL vs VRTX Comparison

UL vs VRTX Comparison

Compare UL & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unilever PLC

UL

Unilever PLC

HOLD

Current Price

$57.58

Market Cap

125.3B

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$445.77

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
UL
VRTX
Founded
1930
1989
Country
United Kingdom
United States
Employees
96092
N/A
Industry
Package Goods/Cosmetics
EDP Services
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
125.3B
115.7B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
UL
VRTX
Price
$57.58
$445.77
Analyst Decision
Buy
Analyst Count
0
29
Target Price
N/A
$539.69
AVG Volume (30 Days)
3.8M
1.2M
Earning Date
03-12-2026
05-04-2026
Dividend Yield
4.04%
N/A
EPS Growth
N/A
836.54
EPS
N/A
4.02
Revenue
N/A
$2,488,652,000.00
Revenue This Year
$2.53
$10.79
Revenue Next Year
$3.78
$10.47
P/E Ratio
$14.29
$110.18
Revenue Growth
N/A
46.20
52 Week Low
$54.75
$362.50
52 Week High
$74.98
$509.98

Technical Indicators

Market Signals
Indicator
UL
VRTX
Relative Strength Index (RSI) 51.47 55.36
Support Level $56.64 $429.02
Resistance Level $58.66 $461.66
Average True Range (ATR) 0.80 9.70
MACD 0.07 1.14
Stochastic Oscillator 73.68 79.53

Price Performance

Historical Comparison
UL
VRTX

About UL Unilever PLC

Unilever is a diversified beauty, wellbeing, and personal care (51% of 2025 sales by value), homecare (23%), and packaged food (26%) company. Its brands include Dove personal-care products, Knorr soups and sauces, Hellmann's mayonnaise, Axe and Rexona deodorants, and TRESemmé haircare. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, and Wild deodorants. The company derives 58% of its sales from emerging markets and 42% from developed markets. The US is its largest market, accounting for around 20% of sales, followed by India, which accounts for 11% of sales.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: